Boston Scientific's Neuromodulation Sales Increased 14% in Q1 FY 2011

Boston Scientific has reported a 14 percent increase of worldwide neuromodulation sales as part of its first quarter FY 2011 financial results, according to a company news release.

Overall, the company achieved sales of $1.925 billion, representing a 2 percent decrease from the first quarter of 2010.

Last month, the U.S. Food and Drug Administration approved Boston Scientific's Clik Anchor for its Precision Plus Spinal Cord Stimulator System. The Precision Plus Spinal Cord Stimulator System masks pain signals by delivering independently controlled pulses of electricity through spinal cord stimulator leads. Anchors are designed to secure leads and minimize unwanted migration.

Read the news release about Boston Scientific's financial results.

Read other coverage about pain management:

- Obama Administration Wants Tighter Control on Prescriptions

- New Nerve Block Technology Shows Promise in Feasibility Studies

- Depression, Chronic Pain Often Go Hand-in-Hand